Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:AMGN
- CUSIP: 03116210
- Web: www.amgen.com
Capitalization:- Market Cap: $122.0673 billion
- Outstanding Shares: 729,674,000
Average Prices:- 50 Day Moving Avg: $173.92
- 200 Day Moving Avg: $168.25
- 52 Week Range: $133.64 - $184.21
P/E:- Trailing P/E Ratio: 15.32
- Foreward P/E Ratio: 13.19
- P/E Growth: 3.27
Sales & Book Value:- Annual Revenue: $23.05 billion
- Price / Sales: 5.32
- Book Value: $43.41 per share
- Price / Book: 3.87
Dividend:- Annual Dividend: $4.60
- Dividend Yield: 2.8%
Profitability:- EBIDTA: $12.36 billion
- Net Margins: 35.46%
- Return on Equity: 29.85%
- Return on Assets: 11.72%
Debt:- Debt-to-Equity Ratio: 1.06%
- Current Ratio: 6.20%
- Quick Ratio: 5.82%
Misc:- Average Volume: 3.17 million shs.
- Beta: 1.35
- Short Ratio: 2.81
Frequently Asked Questions for Amgen (NASDAQ:AMGN)
What is Amgen's stock symbol?
Amgen trades on the NASDAQ under the ticker symbol "AMGN."
How often does Amgen pay dividends? What is the dividend yield for Amgen?
Amgen announced a quarterly dividend on Friday, July 28th. Stockholders of record on Thursday, August 17th will be given a dividend of $1.15 per share on Friday, September 8th. This represents a $4.60 annualized dividend and a dividend yield of 2.74%. The ex-dividend date is Tuesday, August 15th. View Amgen's Dividend History.
How were Amgen's earnings last quarter?
Amgen Inc. (NASDAQ:AMGN) issued its earnings results on Tuesday, July, 25th. The company reported $3.27 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $3.11 by $0.16. The firm had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm's quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.84 earnings per share. View Amgen's Earnings History.
When will Amgen make its next earnings announcement?
Where is Amgen's stock going? Where will Amgen's stock price be in 2017?
22 brokerages have issued 12-month target prices for Amgen's stock. Their forecasts range from $161.00 to $209.00. On average, they expect Amgen's share price to reach $186.72 in the next year. View Analyst Ratings for Amgen.
What are analysts saying about Amgen stock?
Here are some recent quotes from research analysts about Amgen stock:
- 1. Cann analysts commented, "Amgen reported GAAP earnings per share of $2.91, which is 3.2% higher than our estimate of $2.83. Earnings exceeded our expectations due to higher than estimated product sales and a lower than estimated tax rate. Higher than estimated product sales were primarily driven by higher sales of Aranesp, Kyprolis, Blincyto, and Sensipar. Nearly all of Amgen’s products exceeded our estimates for International sales. Total product sales of $5.57 billion exceeded our estimated $5.47 billion by 1.8% and exceeded consensus product sales by 2.7%." (7/26/2017)
- 2. Cowen and Company analysts commented, "Amgen reported Q1 Revenue of $5.46B (-1% Y/Y, vs. consensus of $5.61BE) and." (4/27/2017)
- 3. BMO Capital Markets analysts commented, "We expect the overall survival (OS) benefit in relapsed myeloma patients to enable Kyprolis to grow in the face of generic competition for Velcade. Upside, however, is in our opinion dependent on data in combination with Revlimid+dex (ECOG Ph3) in newly-diagnosed patients given failure of CLARION. Anecdotal data suggests that Darzalex is best suited in IMiD and proteasome inhibitor failures given lack of response of these agents in patients failing Darzalex." (3/6/2017)
- 4. According to Zacks Investment Research, "Amgen growth products – Prolia, Xgeva, Vectibix, Nplate and Sensipar – are performing well. Amgen’s restructuring plan should make it leaner and more cost efficient. Amgen is also progressing with its pipeline given quite a few regulatory and data updates scheduled for the coming quarters. Amgen has a positive record of earnings surprises in recent quarters. Amgen’s shares surpassed that of Biomed-Genetics industry in 2016. However, the company has some challenges in store given the presence of biosimilar competition and slowdown in sales of mature products. Biosimilars are starting to have a negative impact on key products like Neupogen and Neulasta in the EU. Moreover, minimal sales price increases and stiff competition can hurt blockbuster Enbrel sales in 2017. Estimates have also declined lately ahead of the company’s Q4 earnings release." (1/3/2017)
Who are some of Amgen's key competitors?
Some companies that are related to Amgen include Celgene Corporation (CELG), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Exelixis (EXEL), Kite Pharma (KITE), TESARO (TSRO), Bioverativ (BIVV), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Clovis Oncology (CLVS), AveXis (AVXS), Juno Therapeutics (JUNO), Agios Pharmaceuticals (AGIO), BeiGene (BGNE), Intercept Pharmaceuticals (ICPT), GW Pharmaceuticals PLC (GWPH) and China Biologic Products (CBPO).
Who are Amgen's key executives?
Amgen's management team includes the folowing people:
- Robert A. Bradway, Chairman of the Board, President, Chief Executive Officer
- David W. Meline, Executive Vice President, Chief Financial Officer
- Sean E. Harper, Executive Vice President - Research and Development
- Anthony C. Hooper, Executive Vice President - Global Commercial Operations
- Brian M. McNamee, Executive Vice President - Full Potential Initiatives
- Esteban Santos, Executive Vice President, Operations
- Cynthia M. Patton, Senior Vice President, Chief Compliance Officer
- Jonathan P. Graham, Senior Vice President, General Counsel, Secretary
- Lori A. Johnston, Senior Vice President
- David A. Piacquad, Senior Vice President - Business Development
Who owns Amgen stock?
Amgen's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (7.81%), Capital Research Global Investors (7.37%), Vanguard Group Inc. (7.15%), BlackRock Inc. (6.78%), State Street Corp (4.53%) and Northern Trust Corp (1.27%). Company insiders that own Amgen stock include Annette Louise Such, Carbonnel Francois De, Cynthia M Patton, David Baltimore, Madhavan Balachandran and Sean E Harper. View Institutional Ownership Trends for Amgen.
Who sold Amgen stock? Who is selling Amgen stock?
Amgen's stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, AJO LP, Standard Life Investments LTD, State Street Corp, FIL Ltd, American Century Companies Inc., Bank of New York Mellon Corp and Bank of Nova Scotia. View Insider Buying and Selling for Amgen.
Who bought Amgen stock? Who is buying Amgen stock?
Amgen's stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, FMR LLC, Renaissance Technologies LLC, BlackRock Inc., Nordea Investment Management AB, Parametric Portfolio Associates LLC, Ameriprise Financial Inc. and Canada Pension Plan Investment Board. View Insider Buying and Selling for Amgen.
How do I buy Amgen stock?
Shares of Amgen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amgen's stock price today?
One share of Amgen stock can currently be purchased for approximately $168.16.
MarketBeat Community Rating for Amgen (NASDAQ AMGN)MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Amgen (NASDAQ:AMGN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 11 Hold Ratings, 10 Buy Ratings, 1 Strong Buy Rating |
| Consensus Rating: | Buy (Score: 2.55) |
| Consensus Price Target: | $186.72 (11.04% upside) |
Analysts' Ratings History for Amgen (NASDAQ:AMGN)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/21/2017 | Mizuho | Reiterated Rating | Buy | $195.00 -> $183.00 | Low |  |
| 7/27/2017 | Argus | Boost Price Target | Buy | $180.00 -> $195.00 | Low | |
| 7/26/2017 | Oppenheimer Holdings, Inc. | Reiterated Rating | Outperform | $189.00 -> $203.00 | Low | |
| 7/26/2017 | Deutsche Bank AG | Reiterated Rating | Hold | $172.00 -> $174.00 | Low | |
| 7/26/2017 | BMO Capital Markets | Downgrade | Outperform -> Market Perform | | Low | |
| 7/26/2017 | Cann | Reiterated Rating | Buy | $189.00 -> $203.00 | Low | |
| 7/22/2017 | Cowen and Company | Reiterated Rating | Outperform | $209.00 | Low | |
| 7/17/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $195.00 | Low | |
| 7/14/2017 | Credit Suisse Group | Set Price Target | Hold | $177.00 | Low | |
| 7/10/2017 | Morgan Stanley | Reiterated Rating | Overweight | | Low | |
| 6/26/2017 | William Blair | Reiterated Rating | Market Perform | | Low | |
| 6/22/2017 | Leerink Swann | Reiterated Rating | Market Perform | $161.00 | Low | |
| 6/8/2017 | Sanford C. Bernstein | Set Price Target | Hold | $164.00 | Medium | |
| 4/28/2017 | Robert W. Baird | Reiterated Rating | Neutral | $165.00 | Low | |
| 3/20/2017 | Goldman Sachs Group, Inc. (The) | Lower Price Target | Conviction-Buy | $208.00 -> $202.00 | Low | |
| 3/14/2017 | Piper Jaffray Companies | Reiterated Rating | Overweight | $193.00 | Low | |
| 1/31/2017 | Royal Bank Of Canada | Set Price Target | Buy | $190.00 | N/A | |
| 2/1/2017 | Bank of America Corporation | Upgrade | Neutral -> Buy | $156.68 -> $192.00 | N/A | |
| 12/13/2016 | Chardan Capital | Upgrade | Sell -> Neutral | | N/A | |
| 9/28/2016 | Citigroup Inc. | Lower Price Target | Neutral | $175.00 -> $172.00 | N/A | |
| 9/28/2016 | J P Morgan Chase & Co | Reiterated Rating | Hold | | N/A | |
| 8/26/2016 | Gabelli | Initiated Coverage | Hold | | N/A | |
| 7/28/2016 | Barclays PLC | Reiterated Rating | Equal Weight | $185.00 | N/A | |
| 2/23/2016 | BTIG Research | Reiterated Rating | Sell | $135.00 | N/A | |
| 1/22/2016 | Wells Fargo & Company | Reiterated Rating | Hold | | N/A | |
| 12/18/2015 | Atlantic Securities | Initiated Coverage | Overweight | $202.00 | N/A | |
| 9/22/2015 | Nomura | Reiterated Rating | Buy | $190.00 -> $191.00 | N/A | |
| 8/31/2015 | Raymond James Financial, Inc. | Initiated Coverage | Market Perform | | N/A | |
(Data available from 8/22/2015 forward)
Earnings History for Amgen (NASDAQ:AMGN)Earnings History by Quarter for Amgen (NASDAQ AMGN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/25/2017 | | $3.11 | | | | | N/A | |
| 7/25/2017 | Q2 2017 | $3.11 | $3.27 | $5.67 billion | $5.81 billion | View | N/A | |
| 4/26/2017 | Q1 2017 | $3.00 | $3.15 | $5.60 billion | $5.46 billion | View | N/A | |
| 2/2/2017 | Q416 | $2.79 | $2.89 | $5.75 billion | $5.97 billion | View | Listen | |
| 10/27/2016 | Q316 | $2.79 | $3.02 | $5.73 billion | $5.81 billion | View | Listen | |
| 7/27/2016 | Q216 | $2.74 | $2.84 | $5.58 billion | $5.69 billion | View | Listen | |
| 4/28/2016 | Q116 | $2.60 | $2.90 | $5.32 billion | $5.53 billion | View | Listen | |
| 1/28/2016 | Q415 | $2.29 | $2.61 | $5.53 billion | $5.54 billion | View | Listen | |
| 10/28/2015 | Q315 | $2.38 | $2.72 | $5.32 billion | $5.72 billion | View | Listen | |
| 7/30/2015 | Q215 | $2.43 | $2.57 | $5.32 billion | $5.37 billion | View | Listen | |
| 4/21/2015 | Q115 | $2.07 | $2.48 | $4.91 billion | $5.03 billion | View | Listen | |
| 1/27/2015 | Q414 | $2.05 | $2.16 | $5.20 billion | $5.33 billion | View | Listen | |
| 10/27/2014 | Q314 | $2.11 | $2.30 | $4.95 billion | $5.03 billion | View | Listen | |
| 7/29/2014 | Q214 | $2.07 | $2.37 | $4.90 billion | $5.18 billion | View | Listen | |
| 4/22/2014 | Q114 | $1.94 | $1.87 | $4.76 billion | $4.52 billion | View | Listen | |
| 1/28/2014 | Q413 | $1.69 | $1.82 | $4.81 billion | $5.01 billion | View | Listen | |
| 10/22/2013 | Q313 | $1.78 | $1.94 | $4.60 billion | $4.75 billion | View | Listen | |
| 7/30/2013 | Q2 2013 | $1.74 | $1.89 | $4.49 billion | $4.68 billion | View | Listen | |
| 4/23/2013 | Q1 2013 | $1.84 | $1.96 | $4.37 billion | $4.24 billion | View | N/A | |
| 1/23/2013 | Q4 2012 | $1.42 | $1.40 | $4.37 billion | $4.42 billion | View | Listen | |
| 10/23/2012 | | $1.47 | $1.67 | | | View | N/A | |
| 7/26/2012 | | $1.54 | $1.83 | | | View | N/A | |
| 1/26/2012 | | $1.22 | $1.21 | | | View | N/A | |
| 10/24/2011 | | $1.29 | $1.40 | | | View | N/A | |
| 7/29/2011 | | $1.29 | $1.37 | | | View | N/A | |
| 4/20/2011 | | $1.29 | $1.34 | | | View | N/A | |
| 1/24/2011 | | $1.11 | $1.17 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Amgen (NASDAQ:AMGN)2017 EPS Consensus Estimate: $12.28
2018 EPS Consensus Estimate: $12.67
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | $3.04 | $3.17 | $3.09 |
| Q2 2017 | 3 | $3.05 | $3.12 | $3.09 |
| Q3 2017 | 3 | $3.01 | $3.17 | $3.11 |
| Q4 2017 | 3 | $2.97 | $2.99 | $2.98 |
| Q1 2018 | 1 | $3.29 | $3.29 | $3.29 |
| Q2 2018 | 1 | $3.18 | $3.18 | $3.18 |
| Q3 2018 | 1 | $3.10 | $3.10 | $3.10 |
| Q4 2018 | 1 | $3.10 | $3.10 | $3.10 |
(Data provided by Zacks Investment Research)
Current Dividend Information for Amgen (NASDAQ:AMGN)| Next Dividend: | 9/8/2017 |
| Annual Dividend: | $4.60 |
| Dividend Yield: | 2.74% |
| Dividend Growth: | 28.60% (3 Year Average) |
| Payout Ratio: | 41.93% (Trailing 12 Months of Earnings)
36.77% (Based on This Year's Estimates)
36.08% (Based on Next Year's Estimates)
|
| Track Record: | 6 Years of Consecutive Dividend Growth |
Dividend History by Quarter for Amgen (NASDAQ AMGN)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 7/28/2017 | quarterly | $1.15 | 2.64% | 8/15/2017 | 8/17/2017 | 9/8/2017 |
| 3/7/2017 | quarterly | $1.15 | 2.59% | 5/15/2017 | 5/17/2017 | 6/8/2017 |
| 12/20/2016 | quarterly | $1.15 | 3.15% | 2/13/2017 | 2/15/2017 | 3/8/2017 |
| 10/14/2016 | quarterly | $1.00 | 2.46% | 11/14/2016 | 11/16/2016 | 12/8/2016 |
| 7/22/2016 | quarterly | $1.00 | 2.4% | 8/15/2016 | 8/17/2016 | 9/8/2016 |
| 3/2/2016 | quarterly | $1.00 | 2.74% | 5/13/2016 | 5/17/2016 | 6/8/2016 |
| 12/15/2015 | quarterly | $1.00 | 2.43% | 2/11/2016 | 2/16/2016 | 3/8/2016 |
| 10/14/2015 | quarterly | $0.79 | 2.07% | 11/12/2015 | 11/16/2015 | 12/7/2015 |
| 7/28/2015 | quarterly | $0.79 | 1.84% | 8/13/2015 | 8/17/2015 | 9/8/2015 |
| 3/4/2015 | quarterly | $0.79 | 1.98% | 5/12/2015 | 5/14/2015 | 6/5/2015 |
| 12/17/2014 | quarterly | $0.79 | 1.88% | 2/10/2015 | 2/12/2015 | 3/6/2015 |
| 10/17/2014 | quarterly | $0.61 | 1.77% | 11/10/2014 | 11/13/2014 | 12/5/2014 |
| 7/25/2014 | quarterly | $0.61 | 1.99% | 8/12/2014 | 8/14/2014 | 9/5/2014 |
| 3/5/2014 | quarterly | $0.61 | 1.96% | 5/13/2014 | 5/15/2014 | 6/6/2014 |
| 12/13/2013 | quarterly | $0.61 | 2.18% | 2/11/2014 | 2/13/2014 | 3/7/2014 |
| 10/16/2013 | quarterly | $0.47 | 1.62% | 11/12/2013 | 11/14/2013 | 12/6/2013 |
| 7/26/2013 | quarterly | $0.47 | 1.72% | 8/14/2013 | 8/16/2013 | 9/6/2013 |
| 3/6/2013 | quarterly | $0.47 | 2.02% | 5/14/2013 | 5/16/2013 | 6/7/2013 |
| 12/13/2012 | quarterly | $0.47 | 2.11% | 2/11/2013 | 2/13/2013 | 3/7/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Amgen (NASDAQ:AMGN)Insider Ownership Percentage: 0.20%
Institutional Ownership Percentage: 79.12%
Insider Trades by Quarter for Amgen (NASDAQ:AMGN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/24/2017 | Cynthia M Patton | SVP | Sell | 2,922 | $154.40 | $451,156.80 | |
| 8/2/2016 | Annette Louise Such | VP | Sell | 3,000 | $174.59 | $523,770.00 | |
| 5/4/2016 | Madhavan Balachandran | EVP | Sell | 30,000 | $154.12 | $4,623,600.00 | |
| 4/29/2016 | David Baltimore | Director | Sell | 3,312 | $157.21 | $520,679.52 | |
| 4/29/2016 | Sean E Harper | EVP | Sell | 21,875 | $157.99 | $3,456,031.25 | |
| 8/31/2015 | Carbonnel Francois De | Director | Sell | 5,000 | $153.84 | $769,200.00 | |
| 8/19/2015 | Fred Hassan | Director | Buy | 3,010 | $166.63 | $501,556.30 | |
| 6/2/2015 | Cynthia M Patton | SVP | Sell | 4,530 | $157.06 | $711,481.80 | |
| 4/23/2015 | Stuart A Tross | SVP | Sell | 3,012 | $169.31 | $509,961.72 | |
| 4/22/2015 | Sean E Harper | EVP | Sell | 28,000 | $171.58 | $4,804,240.00 | |
| 3/3/2015 | Stuart A Tross | SVP | Sell | 4,415 | $157.74 | $696,422.10 | |
| 3/2/2015 | David Baltimore | Director | Sell | 3,647 | $158.76 | $578,997.72 | |
| 2/11/2015 | Robert A Bradway | CEO | Sell | 22,000 | $152.69 | $3,359,180.00 | |
| 2/5/2015 | Frank C Herringer | Director | Buy | 3,000 | $152.29 | $456,870.00 | |
| 12/3/2014 | Carbonnel Francois De | Director | Sell | 3,000 | $168.01 | $504,030.00 | |
| 8/5/2014 | Cynthia M Patton | SVP | Sell | 2,644 | $127.97 | $338,352.68 | |
| 8/5/2014 | Sean E Harper | EVP | Sell | 14,000 | $127.29 | $1,782,060.00 | |
| 5/21/2014 | Thomas J.W. Dittrich | CAO | Sell | 4,130 | $112.83 | $465,987.90 | |
| 4/28/2014 | A Kelly Michael | CFO | Sell | 2,065 | $110.45 | $228,079.25 | |
| 3/6/2014 | Carbonnel Francois De | Director | Sell | 1,000 | $126.69 | $126,690.00 | |
| 9/4/2013 | Madhavan Balachandran | EVP | Sell | 18,000 | $112.76 | $2,029,680.00 | |
| 8/28/2013 | David Baltimore | Director | Sell | 4,582 | $109.66 | $502,462.12 | |
| 5/22/2013 | Thomas J.W. Dittrich | CAO | Sell | 6,130 | $104.78 | $642,301.40 | |
| 5/21/2013 | Madhavan Balachandran | EVP | Sell | 6,000 | $103.28 | $619,680.00 | |
| 5/17/2013 | Rebecca M Henderson | Director | Sell | 8,421 | $105.72 | $890,268.12 | |
| 5/16/2013 | Cynthia M Patton | SVP | Sell | 3,544 | $105.01 | $372,155.44 | |
| 5/14/2013 | Judith C Pelham | Director | Sell | 25,000 | $108.25 | $2,706,250.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Amgen (NASDAQ:AMGN)
Latest Headlines for Amgen (NASDAQ:AMGN)
| Source: |
|
| Date | Headline |
|---|
 | Amgen To Present New Data From The Repatha® (Evolocumab) Cardiovascular Outcomes Study At ESC Congress 2017
finance.yahoo.com - August 21 at 3:59 PM |
 | Amgen Inc. (AMGN) Rating Reiterated by Mizuho
www.americanbankingnews.com - August 21 at 11:10 AM |
 | Amgen (AMGN), Humana (HUM) Partner For Improved Health Outcomes And Efficiency
www.streetinsider.com - August 18 at 3:18 AM |
| How Amgen’s Nephrology Drugs Are Positioned after 2Q17?
finance.yahoo.com - August 17 at 5:15 PM |
| Where Amgen’s Enbrel and Nplate Stand after 2Q17
finance.yahoo.com - August 17 at 5:15 PM |
| Amgen And Humana Partner For Improved Health Outcomes And Efficiency
finance.yahoo.com - August 17 at 5:14 PM |
| Repatha® (Evolocumab) Phase 3 Cognitive Function Study Results Published In The New England Journal Of Medicine
finance.yahoo.com - August 16 at 8:56 PM |
| What Amgen Expects from Blincyto in 2017
finance.yahoo.com - August 16 at 3:53 PM |
| How Amgen’s Neutropenia Drugs Are Positioned after 2Q17
finance.yahoo.com - August 16 at 3:53 PM |
| Biogen: Goldman Has Conviction!
finance.yahoo.com - August 16 at 3:53 PM |
| What We May See from Amgen’s Vectibix in 2017
finance.yahoo.com - August 16 at 3:53 PM |
| Amgen Inc. (AMGN) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 16 at 12:42 AM |
 | Are Amgen's New Drugs Doing Well Enough to Drive Sales?
www.zacks.com - August 15 at 4:52 PM |
| What Kyprolis Could Do for Amgen’s Revenue Growth
finance.yahoo.com - August 15 at 4:52 PM |
| Are Amgen's New Drugs Doing Well Enough to Drive Sales?
finance.yahoo.com - August 15 at 4:52 PM |
| Gauging Amgen’s Xgeva Contribution in 2017
finance.yahoo.com - August 15 at 4:52 PM |
| Can Ligand's Captisol Deals Boost Growth in the Long Run?
finance.yahoo.com - August 15 at 4:52 PM |
| Inside Amgen’s 2Q17 Performance
finance.yahoo.com - August 15 at 2:15 AM |
| Behind Amgen’s High Revenue Growth from Prolia in 2Q17
finance.yahoo.com - August 15 at 2:15 AM |
| Dividend Coverage: This Biotech Drugmaker Pays Higher Dividend than the Healthcare Sector by Over 316%; Will Trade Ex-Dividend on August 15, 2017
finance.yahoo.com - August 14 at 9:14 PM |
 | Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for August 15, 2017 - Nasdaq
www.nasdaq.com - August 14 at 4:13 PM |
| The Zacks Analyst Blog Highlights: Disney, Amgen, Caterpillar, S&P Global and Emerson Electric
finance.yahoo.com - August 14 at 4:13 PM |
| What Amgen’s Analysts Recommend in August 2017
finance.yahoo.com - August 14 at 4:13 PM |
| IHS Markit Score Update: Drop in demand for ETFs holding Amgen Inc is a negative sign for its shares
finance.yahoo.com - August 12 at 2:19 AM |
| ETFs with exposure to Amgen, Inc. : August 11, 2017
finance.yahoo.com - August 12 at 2:19 AM |
| Amgen, Inc. breached its 50 day moving average in a Bearish Manner : AMGN-US : August 11, 2017
finance.yahoo.com - August 11 at 4:17 PM |
| See what the IHS Markit Score report has to say about Amgen Inc.
finance.yahoo.com - August 10 at 10:22 PM |
 | Major Biotechs Send Short Sellers Running for Cover - 24/7 Wall St.
247wallst.com - August 10 at 5:18 PM |
 | Trade of the Day: Amgen, Inc. (AMGN) Stock Is a Quiet Bull - Investorplace.com
investorplace.com - August 10 at 5:17 PM |
| Trade of the Day: Amgen, Inc. (AMGN) Stock Is a Quiet Bull
investorplace.com - August 10 at 7:42 AM |
| Analysts’ Recommendations for Celgene in August 2017
finance.yahoo.com - August 9 at 4:01 PM |
| Amgen Remains A Standout Among Biotechs
finance.yahoo.com - August 8 at 3:43 PM |
| Ligand (LGND) Q2 Earnings & Revenues Top, 2017 View Raised
finance.yahoo.com - August 8 at 3:43 PM |
| Valeant Pops on Earnings Beat, Debt Reduction Effort
finance.yahoo.com - August 8 at 3:43 PM |
 | Here's Why Coherus Biosciences Rose as Much as 22.2% Today
www.fool.com - August 8 at 11:53 AM |
| Scottish Medicines Consortium Accepts Amgen's Multiple Myeloma Treatment, KYPROLIS® ▼ (carfilzomib), in Combination with Dexamethasone, for use at First Relapse
finance.yahoo.com - August 8 at 2:45 AM |
| Coherus BioSciences (CHRS) Files Petition for IPR of Amgen's (AMGN) ENBREL Patent 8,163,522
www.streetinsider.com - August 7 at 4:42 PM |
| Why A Tax Holiday Alone Won't Spark Biotech M&A
finance.yahoo.com - August 7 at 4:41 PM |
| Here's Why Array BioPharma Inc. Fell 13.7% in July
finance.yahoo.com - August 7 at 4:41 PM |
| Amgen Inc. (AMGN) Expected to Announce Quarterly Sales of $5.74 Billion
www.americanbankingnews.com - August 4 at 7:58 AM |
| The Surprising Reason Regeneron Toppled Despite Its Beat-And-Raise
finance.yahoo.com - August 3 at 5:01 PM |
| Earnings Preview: What To Expect From Teva Pharmaceutical On Thursday
finance.yahoo.com - August 2 at 3:43 PM |
 | Amgen: A Dividend Powerhouse Despite A Maturing Portfolio - Seeking Alpha
seekingalpha.com - July 31 at 8:56 PM |
| Amgen Looks To Enhance Its Cholesterol Drug - Seeking Alpha
seekingalpha.com - July 31 at 8:56 PM |
| Amgen Submits Supplemental Biologics License Application For Prolia® (denosumab) In Glucocorticoid-Induced Osteoporosis
finance.yahoo.com - July 31 at 3:53 PM |
| Amgen files U.S. marketing application for expanded use of osteoporosis med Prolia
seekingalpha.com - July 31 at 9:47 AM |
| Amgen: Income On Sale - Seeking Alpha
seekingalpha.com - July 28 at 9:59 PM |
| Amgen Inc. (AMGN) Announces $1.15 Quarterly Dividend
www.americanbankingnews.com - July 28 at 5:46 PM |
| Amgen, Inc. :AMGN-US: Earnings Analysis: Q2, 2017 By the Numbers : July 28, 2017
finance.yahoo.com - July 28 at 4:54 PM |
| Court Ruling on 'Biosimilars' Sets Stage for More Drug Acquisitions
finance.yahoo.com - July 28 at 4:54 PM |
Amgen (AMGN) Chart for Tuesday, August, 22, 2017
